Review
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 1896-1918
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1896
Table 5 Chemoembolization plus systemic therapies
Trial
Experimental arms, n (%)
Outcomes
TACE + sorafenib
SPACE trial (Lencioni et al[80], 2016) DEB-TACE plus sorafenib (154) vs DEB-TACE plus placebo (153)5.6 mo vs 5.5 mo; HR: 0.797 (95%CI: 0.588–1.080); P = 0.072
TACE 2 trial (Meyer et al[81], 2017) DEB-TACE plus sorafenib (157) vs DEB-TACE plus placebo (156)7.8 mo vs 7.7 mo; HR: 1.03 (95%CI: 0.75–1.42); P = 0.85
STAH trial (Park et al[82], 2019) cTACE plus sorafenib (170) vs sorafenib (169)12.8 mo vs 10.8 mo; HR: 0.91 (95%CI: 0.69–1.21); P = 0.290
TACTICS trial (Kudo et al[83], 2020) cTACE plus sorafenib (80) vs cTACE (76)25.2 mo vs 13.5 mo; HR: 0.59 (95%CI: 0.41–0.87); P = 0.006
TACE + other therapies
BRISK-TA trial (Kudo et al[85], 2014)cTACE or DEB-TACE plus brivanib (249) vs cTACE plus placebo (253)26.4 mo vs 26.1 mo; HR: 0.90 (95%CI: 0.66-1.23); P = 0.53
ORIENTAL trial (Kudo et al[86], 2018) cTACE plus orantinib (445) vs cTACE plus placebo (444)31.1 mo vs 32.3 mo; HR: 1.090 (95%CI: 0.878–1.352); P = 0.435
TACE combined with celecoxib and lanreotide (Tong et al[89], 2017) TACE (n = 35) vs TACE + C + L (36)7.5 mo vs 15.0 mo; HR: 0.534 (95%CI: 0.321-0.888); P = 0.016
TACE combined with thalidomide (Wu et al[87], 2014) TACE + thalidomide (56)21 mo (95%CI: 16–28 mo)
TACE plus bevacizumab (Pinter et al[88], 2015) TACE + bevacizumab (20) vs TACE + placebo (20)5.3 mo vs 13.7 mo; HR: 1.7 (95%CI: 0.8-3.6); P = 0.195
HR: Hepatic resection; TACE: Transarterial chemoembolization.